OWCP — OWC Pharmaceutical Research Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$1.46m
Annual income statement for OWC Pharmaceutical Research, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2014 December 31st | 2015 December 31st | 2016 December 31st | 2017 December 31st | 2018 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.05 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.03 | 1.65 | 2.15 | 4.55 | 4.3 |
Operating Profit | -5.03 | -1.65 | -2.1 | -4.55 | -4.3 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.07 | -1.65 | -2.29 | -4.56 | -10.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.07 | -1.65 | -2.29 | -4.56 | -10.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.07 | -1.65 | -2.29 | -4.56 | -10.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -5.07 | -1.65 | -2.29 | -4.56 | -12.7 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.063 | -0.021 | -0.024 | -0.031 | -0.081 |
Dividends per Share |